External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

BACKGROUND AND AIMS: Trastuzumab provides clinical benefit for advanced and early breast cancer patients whose tumours over‐express or have gene amplification of the HER2 oncogene. The UK National External Quality Assessment Scheme (NEQAS) for immunohistochemical testing was established to assess an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bartlett, John M S, Ibrahim, Merdol, Jasani, Bharat, Morgan, John M, Ellis, Ian, Kay, Elaine, Magee, Hilary, Barnett, Sarah, Miller, Keith
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2007
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1995794/
https://ncbi.nlm.nih.gov/pubmed/16963466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2006.040840
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados